-+ 0.00%
-+ 0.00%
-+ 0.00%

Maxim Group Maintains Buy on Definium Therapeutics, Raises Price Target to $55

Benzinga·08/14/2026 20:12:18
Listen to the news
Maxim Group maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $50 to $55.